US › Healthcare

Bio-Rad Laboratories Inc (BIO)

US · Healthcare · Medical Devices

$332.88-0.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$592.1M
Revenue YoY
+1.1%
Net profit
$-527.1M
Profit YoY
-923.6%
EPS
$1.89
EPS estimate
$1.99
Net margin
-89.0%

EPS came in at 1.89 against a street estimate of 1.99 — a miss of 5.0%.

Key statistics

Market cap
$8.96B
P/E
55.6
Forward P/E
36.8
P/B
1.27
Book value
$255.37
EPS (TTM)
$6.02
52-week high
$343.12
52-week low
$236.73
50-day MA
$299.20
200-day MA
$295.69
Beta
1.05

Analyst view

Analysts rate Bio-Rad Laboratories Inc a buy (4 buy, 2 hold, 0 sell out of 6) with an average price target of $297.00.

Shareholding

Insiders
16.34%
Institutions
94.46%

Largest institutional holders

FundStake
Arnhold & S. Bleichroeder Advisers, LLC9.73%
Vanguard Group Inc6.63%
BlackRock Inc6.28%
Dimensional Fund Advisors, Inc.4.07%
Vanguard Capital Management, LLC3.11%
Vanguard Portfolio Management, LLC3.10%
Ariel Investments, LLC2.94%
Earnest Partners LLC2.20%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bio-Rad Laboratories Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.